Odysseas Kostas, M.D.

Dr. Kostas joined the board of directors of Armata Pharmaceuticals in February 2020. At Innoviva, Inc. (NASDAQ: INVA), a company with a portfolio of royalties that include respiratory assets partnered with Glaxo Group Limited, Dr. Kostas has served as a member of the Board of Directors since December 2017 and as Chairman of the Board of Directors since April 2018. He is currently a member of Innoviva’s Audit Committee and Nominating/Corporate Governance Committee. Dr. Kostas is a Partner and Senior Analyst at Sarissa Capital Management LP focused on improving the strategies of companies to enhance shareholder value. Prior to joining Sarissa Capital, Dr. Kostas served as a Director at Evercore ISI (formerly ISI), covering the biotechnology and pharmaceutical industries. Previously, he practiced internal medicine as part of the Yale New Haven Health System and was engaged as a consultant to various biotechnology companies. Dr. Kostas currently serves on the board of directors of Enzon Pharmaceuticals (NASDAQ: ENZN).